Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsChristoph Röllig, Ulrich S. Schuler, Regina Herbst et al.|Annals of Oncology|2018Cited by 37
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ TrialChristoph Röllig, Ulrich S. Schuler, Michael Krämer et al.|Blood|2015Cited by 4